Emergent BioSolutions Inc. (EBS)Healthcare | Drug Manufacturers - Specialty & Generic | Gaithersburg, United States | NYSE
7.18 USD
+0.27
(3.907%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:25 a.m. EDT
The investment case for Emergent BioSolutions is currently broken by deteriorating fundamentals and a hostile market reaction to recent guidance cuts. While the company boasts impressive top-line growth of 66%, this is being completely overshadowed by a massive non-cash impairment charge related to NARCAN assets and a sharp reduction in forward guidance. The balance sheet is strained with debt significantly exceeding cash reserves, and the return on equity is deeply negative, signaling that the core business is destroying shareholder value despite the revenue surge. The short-term outlook is bleak; the stock is trading well below its 200-day average, confirming a sustained downtrend, and the statistical forecasting model leans slightly negative with low confidence, which aligns with the broader technical weakness. There is no dividend to provide any cushion against the volatility. Long-term, the multi-year price trajectory reflects the market's verdict: the asset is a value trap where the low price-to-book ratio is not a margin of safety but a reflection of eroding competitive moats and execution risks. The heavy put positioning in the options chain confirms that sophisticated traders are betting on further downside rather than a recovery. Until the impairment is resolved and guidance stabilizes, the risk-reward profile remains skewed heavily toward the downside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.174276 |
| AutoARIMA | 0.207917 |
| MSTL | 0.208454 |
| AutoETS | 0.208557 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.086 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 172.291 |
| Revenue per Share | 14.755 |
| Market Cap | 368,142,528 |
| Forward P/E | 6.86 |
| Beta | 2.29 |
| Profit Margins | -22.96% |
| Website | https://www.emergentbiosolutions.com |
As of Oct. 10, 2026, 9:25 a.m. EDT: Speculators are overwhelmingly bearish, positioning heavy out-of-the-money puts for December 2026 and January 2027 expirations while virtually ignoring calls beyond the immediate term. The massive volume in deep OTM puts suggests a fear of a significant downside gap, whereas call activity is concentrated near the money or slightly out, indicating limited bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.23617023 |
| Address1 | 300 Professional Drive |
| Address2 | Suite 400 |
| All Time High | 137.61 |
| All Time Low | 1.42 |
| Ask | 0.0 |
| Ask Size | 500 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,098,570 |
| Average Daily Volume3 Month | 1,149,829 |
| Average Volume | 1,149,829 |
| Average Volume10Days | 1,098,570 |
| Beta | 2.286 |
| Bid | 6.97 |
| Bid Size | 600 |
| Board Risk | 3 |
| Book Value | 6.655 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.18 |
| Current Ratio | 5.423 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.225 |
| Day Low | 6.84 |
| Debt To Equity | 172.291 |
| Display Name | Emergent BioSolutions |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,656,800 |
| Earnings Call Timestamp Start | 1,793,656,800 |
| Earnings Timestamp | 1,793,649,600 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | 234,900,000 |
| Ebitda Margins | 0.30499 |
| Enterprise To Ebitda | 3.477 |
| Enterprise To Revenue | 1.06 |
| Enterprise Value | 816,642,560 |
| Eps Current Year | 0.3596 |
| Eps Forward | 1.04643 |
| Eps Trailing Twelve Months | -3.4 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 240 631 3203 |
| Fifty Day Average | 6.0666 |
| Fifty Day Average Change | 1.1134 |
| Fifty Day Average Change Percent | 0.1835295 |
| Fifty Two Week Change Percent | -23.617023 |
| Fifty Two Week High | 14.06 |
| Fifty Two Week High Change | -6.8800006 |
| Fifty Two Week High Change Percent | -0.48933145 |
| Fifty Two Week Low | 4.36 |
| Fifty Two Week Low Change | 2.8199997 |
| Fifty Two Week Low Change Percent | 0.6467889 |
| Fifty Two Week Range | 4.36 - 14.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,163,601,000,000 |
| Float Shares | 49,050,637 |
| Forward Eps | 1.04643 |
| Forward P E | 6.861424 |
| Free Cashflow | 40,000,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 900 |
| Fullday Change | -0.029999733 |
| Fullday Change Percent | -0.41782358 |
| Fullday Price | 7.15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.50441 |
| Gross Profits | 388,500,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0421 |
| Held Percent Institutions | 0.90516 |
| Implied Shares Outstanding | 51,273,336 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-irhome#node/150 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Emergent BioSolutions Inc. |
| Market | us_market |
| Market Cap | 368,142,528 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_13627017 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -176,800,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 341,993,151 |
| Number Of Analyst Opinions | 2 |
| Open | 6.96 |
| Operating Cashflow | 97,700,000 |
| Operating Margins | 0.2834 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.38 |
| Phone | 240 631 3200 |
| Pre Market Change | -0.029999733 |
| Pre Market Change Percent | -0.41782358 |
| Pre Market Price | 7.15 |
| Pre Market Time | 1,792,140,704 |
| Previous Close | 6.91 |
| Price Eps Current Year | 19.966629 |
| Price Hint | 2 |
| Price To Book | 1.0788879 |
| Price To Sales Trailing12 Months | 0.47798303 |
| Profit Margins | -0.22955 |
| Quick Ratio | 2.685 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.27 |
| Regular Market Change Percent | 3.90738 |
| Regular Market Day High | 7.225 |
| Regular Market Day Low | 6.84 |
| Regular Market Day Range | 6.84 - 7.225 |
| Regular Market Open | 6.96 |
| Regular Market Previous Close | 6.91 |
| Regular Market Price | 7.18 |
| Regular Market Time | 1,792,094,402 |
| Regular Market Volume | 654,811 |
| Return On Assets | 0.06931 |
| Return On Equity | -0.40292 |
| Revenue Growth | 0.663 |
| Revenue Per Share | 14.755 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 51,273,336 |
| Shares Percent Shares Out | 0.18129998 |
| Shares Short | 9,293,986 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,842,235 |
| Short Name | Emergent BioSolutions Inc. |
| Short Percent Of Float | 0.1841 |
| Short Ratio | 8.24 |
| Source Interval | 15 |
| State | MD |
| Symbol | EBS |
| Target High Price | 12.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 139,700,000 |
| Total Cash Per Share | 2.725 |
| Total Debt | 588,200,000 |
| Total Revenue | 770,200,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.356 |
| Two Hundred Day Average Change | -1.1760001 |
| Two Hundred Day Average Change Percent | -0.1407372 |
| Type Disp | Equity |
| Volume | 654,811 |
| Website | https://www.emergentbiosolutions.com |
| Zip | 20,879 |